GlobalData
GlobalData

Rebecca Panks

  • Home
  • Author: Rebecca Panks

UK insurance brokers aim to bounce back from unique challenges in 2020, says GlobalData

National insurance brokers in the UK are once again looking towards upselling, acquisition and marketing to grow their business and recover from an extremely challenging 2020, according to GlobalData survey data. GlobalData’s 2021 UK Commercial Brokers Survey found that the three most popular growth strategies for national brokers (cross-selling/upselling, acquisition, and increasing marketing activity/web presence) […]
Read more

Microsoft’s purchase of Nuance Communications will strengthen its enterprise strategy, says GlobalData

Following the news that Microsoft has acquired conversational platforms specialist Nuance Communications; David Bicknell, Principal Analyst, Thematic Research at GlobalData, a leading data and analytics company, offers his view: “Conversational platforms is one of the most commonly used artificial intelligence (AI) technologies and one of the most significant themes expected to have a massive impact […]
Read more

SPACs losing momentum as Investors shy away, says GlobalData

Special purpose acquisition company (SPAC) initial public offerings (IPOs) from Jan to Apr 2021 exceeded $87bn* Valuations may rise, with many SPACs looking for targets in similar spaces Key attractions include technology, media and telecoms (TMT); pharma; and sustainability US stock exchanges saw a total of 301 SPAC IPOs priced, raising $87.6bn in the first […]
Read more

Asthma low patient adherence shows need for personalized and convenient medications, says GlobalData

Primary research by data and analytics company GlobalData has revealed that 80% of asthma patients do not take their medication effectively. The reasons for this poor patient adherence are numerous and can include poor inhaler technique, poor perception, complex regimens and the cost of medication. Tiffany Chan, Immunology Analyst at GlobalData, discusses what medicines are […]
Read more

Newron’s Xadago set to reach $246m by 2029 with new label extension potential in PD-LID, says GlobalData

Newron Pharmaceuticals and Zambon’s planned pivotal trial to evaluate a label extension for Xadago (safinamide) in patients with Parkinson’s disease levodopa-induced dyskinesia (PD-LID) is a strategic approach to boost Xadago’s peak sales and strengthen its competitive advantage in the PD space. This strategy usually helps companies to expand their existing patient pool and capitalize on […]
Read more

COVID-19 is disproportionately affecting women with major depressive disorder, says GlobalData

The coronavirus disease 2019 (COVID-19) is likely to have far-reaching consequences for the mental health of women with major depressive disorder (MDD), which is expected to increase in prevalence after the pandemic, says GlobalData, a leading data and analytics company. Ana Fernandez Menjivar, MSc DLSHTM, Senior Epidemiologist at GlobalData, comments: “The higher prevalence of MDD […]
Read more
1 25 26 27 28 29 77